These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25965315)

  • 1. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
    Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
    Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
    Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.
    Hioe CE; Wrin T; Seaman MS; Yu X; Wood B; Self S; Williams C; Gorny MK; Zolla-Pazner S
    PLoS One; 2010 Apr; 5(4):e10254. PubMed ID: 20421997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
    Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
    Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
    Upadhyay C; Mayr LM; Zhang J; Kumar R; Gorny MK; Nádas A; Zolla-Pazner S; Hioe CE
    J Virol; 2014 Nov; 88(21):12853-65. PubMed ID: 25165106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
    Krachmarov CP; Honnen WJ; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2006 Jul; 80(14):7127-35. PubMed ID: 16809318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
    Moody MA; Gao F; Gurley TC; Amos JD; Kumar A; Hora B; Marshall DJ; Whitesides JF; Xia SM; Parks R; Lloyd KE; Hwang KK; Lu X; Bonsignori M; Finzi A; Vandergrift NA; Alam SM; Ferrari G; Shen X; Tomaras GD; Kamanga G; Cohen MS; Sam NE; Kapiga S; Gray ES; Tumba NL; Morris L; Zolla-Pazner S; Gorny MK; Mascola JR; Hahn BH; Shaw GM; Sodroski JG; Liao HX; Montefiori DC; Hraber PT; Korber BT; Haynes BF
    Cell Host Microbe; 2015 Sep; 18(3):354-62. PubMed ID: 26355218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
    J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.
    Spencer DA; Malherbe DC; Vázquez Bernat N; Ádori M; Goldberg B; Dambrauskas N; Henderson H; Pandey S; Cheever T; Barnette P; Sutton WF; Ackerman ME; Kobie JJ; Sather DN; Karlsson Hedestam GB; Haigwood NL; Hessell AJ
    J Immunol; 2021 Mar; 206(5):999-1012. PubMed ID: 33472907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
    Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
    PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
    Haldar B; Burda S; Williams C; Heyndrickx L; Vanham G; Gorny MK; Nyambi P
    PLoS One; 2011 Feb; 6(2):e17253. PubMed ID: 21383841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
    Gorny MK; Wang XH; Williams C; Volsky B; Revesz K; Witover B; Burda S; Urbanski M; Nyambi P; Krachmarov C; Pinter A; Zolla-Pazner S; Nadas A
    Mol Immunol; 2009 Feb; 46(5):917-26. PubMed ID: 18952295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.